

Peter T Vickerman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6363307/publications.pdf>

Version: 2024-02-01

295
papers

15,950
citations

27035

58
h-index

24511

114
g-index

306
all docs

306
docs citations

306
times ranked

13729
citing authors

#	ARTICLE	IF	CITATIONS
1	An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis. <i>Addiction</i> , 2022, 117, 411-424.	1.7	6
2	Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. <i>Addiction</i> , 2022, 117, 1338-1352.	1.7	11
3	The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e136-e145.	4.7	14
4	Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis. <i>Lancet HIV</i> , the, 2022, 9, e42-e53.	2.1	18
5	Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 353-366.	3.7	10
6	Perceived availability and carriage of take-home naloxone and factors associated with carriage among people who inject drugs in England, Wales and Northern Ireland. <i>International Journal of Drug Policy</i> , 2022, 102, 103615.	1.6	0
7	The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs - findings from a national survey in England, Wales, and Northern Ireland. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	0
8	Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya. <i>Journal of Viral Hepatitis</i> , 2022, 29, 691-694.	1.0	6
9	Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The STOP-C Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 1809-1819.	2.9	11
10	Modeling the impact of interventions during an outbreak of HIV infection among people who inject drugs in 2012-2013 in Athens, Greece.. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109396.	1.6	2
11	Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 426-445.	3.7	50
12	Gonococcal Vaccines for Controlling <i>Neisseria gonorrhoeae</i> in Men Who Have Sex With Men: A Promising Game Changer. <i>Journal of Infectious Diseases</i> , 2022, 225, 931-933.	1.9	1
13	A cross-sectional study comparing men who have sex with men and inject drugs and people who inject drugs who are men and have sex with men in San Francisco: Implications for HIV and hepatitis C virus prevention. <i>Health Science Reports</i> , 2022, 5, .	0.6	7
14	Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky. <i>International Journal of Drug Policy</i> , 2021, 88, 102707.	1.6	14
15	The use of mathematical modeling to inform drug policy making. <i>International Journal of Drug Policy</i> , 2021, 88, 102759.	1.6	0
16	Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2021, 116, 1664-1676.	1.7	9
17	Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan. <i>Journal of Viral Hepatitis</i> , 2021, 28, 268-278.	1.0	10
18	Estimating the contribution of key populations towards HIV transmission in South Africa. <i>Journal of the International AIDS Society</i> , 2021, 24, e25650.	1.2	28

#	ARTICLE	IF	CITATIONS
19	Modelling the impact of an HIV testing intervention on HIV transmission among men who have sex with men in China. <i>HIV Medicine</i> , 2021, 22, 467-477.	1.0	5
20	Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar. <i>BMJ Global Health</i> , 2021, 6, e004181.	2.0	4
21	Hepatitis C Care Cascades for 3 Populations at High Risk: Low-income Trans Women, Young People Who Inject Drugs, and Men Who Have Sex With Men and Inject Drugs. <i>Clinical Infectious Diseases</i> , 2021, 73, e1290-e1295.	2.9	10
22	Discovering environmental management opportunities for infectious disease control. <i>Scientific Reports</i> , 2021, 11, 6442.	1.6	4
23	Impact of screening on the prevalence and incidence of <i>Mycoplasma genitalium</i> and its macrolide resistance in men who have sex with men living in Australia: A mathematical model. <i>EClinicalMedicine</i> , 2021, 33, 100779.	3.2	14
24	Assessing the potential impact of disruptions due to COVID-19 on HIV among key and lower-risk populations in the largest cities of Cameroon and Benin. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 899-911.	0.9	11
25	Exploratory comparison of Healthcare costs and benefits of the UK's Covid-19 response with four European countries. <i>European Journal of Public Health</i> , 2021, 31, 619-624.	0.1	13
26	The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK. <i>Journal of Viral Hepatitis</i> , 2021, 28, 897-908.	1.0	3
27	Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. <i>Lancet Psychiatry</i> , 2021, 8, 301-309.	3.7	20
28	The impact of disruptions due to COVID-19 on HIV transmission and control among men who have sex with men in China. <i>Journal of the International AIDS Society</i> , 2021, 24, e25697.	1.2	27
29	Quantifying the Evolving Contribution of HIV Interventions and Key Populations to the HIV Epidemic in Yaoundé, Cameroon. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 396-405.	0.9	8
30	Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Public Health</i> , 2021, 6, e309-e323.	4.7	99
31	Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). <i>PLoS Medicine</i> , 2021, 18, e1003653.	3.9	29
32	Overlapping Key Populations and HIV Transmission in Tijuana, Mexico: A Modelling Analysis of Epidemic Drivers. <i>AIDS and Behavior</i> , 2021, 25, 3814-3827.	1.4	7
33	Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C. <i>BMJ Open</i> , 2021, 11, e041490.	0.8	2
34	Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 533-546.	3.7	48
35	Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection. <i>International Journal of Drug Policy</i> , 2021, 96, 103419.	1.6	2
36	Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons. <i>Hepatology</i> , 2021, 74, 2366-2379.	3.6	9

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison. <i>International Journal of Drug Policy</i> , 2021, 96, 103394.	1.6	8
38	The impact of recent homelessness on the provision of injection drug use initiation assistance among persons who inject drugs in Tijuana, Mexico and Vancouver, Canada. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108829.	1.6	4
39	Elucidating Drivers for Variations in the Explosive Human Immunodeficiency Virus Epidemic Among People Who Inject Drugs in Pakistan. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab457.	0.4	0
40	What Is the Burden of Heterosexually Acquired HIV Due to HSV-2? Global and Regional Model-Based Estimates of the Proportion and Number of HIV Infections Attributable to HSV-2 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 19-30.	0.9	9
41	Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, e107-e118.	2.9	39
42	Mathematical Model Impact Analysis of a Real-Life Pre-exposure Prophylaxis and Treatment-As-Prevention Study Among Female Sex Workers in Cotonou, Benin. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, e28-e42.	0.9	5
43	Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis. <i>PLoS Medicine</i> , 2021, 18, e1003818.	3.9	8
44	Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania. <i>Journal of the International AIDS Society</i> , 2021, 24, e25817.	1.2	5
45	Modelling the effect of market forces on the impact of introducing human immunodeficiency virus pre-exposure prophylaxis among female sex workers. <i>Health Economics (United Kingdom)</i> , 2021, 30, 659-679.	0.8	1
46	Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?. <i>Eurosurveillance</i> , 2021, 26, .	3.9	4
47	Hepatitis C virus elimination in Indonesia: Epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning. <i>Liver International</i> , 2020, 40, 286-297.	1.9	7
48	Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation. <i>Addiction</i> , 2020, 115, 702-713.	1.7	8
49	Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. <i>The Lancet Global Health</i> , 2020, 8, e244-e253.	2.9	16
50	Risk compensation and STI incidence in PrEP programmes. <i>Lancet HIV</i> , 2020, 7, e222-e223.	2.1	25
51	Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxis. <i>EclinicalMedicine</i> , 2020, 19, 100217.	3.2	13
52	Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2020, 23, 180-190.	0.1	1
53	Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2020, 8, e76-e91.	2.9	19
54	Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. <i>Lancet Infectious Diseases</i> , 2020, 20, 240-249.	4.6	88

#	ARTICLE	IF	CITATIONS
55	Phylogenetic analysis of HIV-1 subtypes B, C and CRF 02_AG in Senegal. <i>Epidemics</i> , 2020, 30, 100376.	1.5	3
56	Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 294-315.	1.0	81
57	Frequency of injecting among people who inject drugs: A systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2020, 76, 102619.	1.6	21
58	Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2020, 84, 102866.	1.6	17
59	HIV prevention is not all about HIV " using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection. <i>BMC Infectious Diseases</i> , 2020, 20, 704.	1.3	17
60	HEPCARE EUROPE- A case study of a service innovation project aiming at improving the elimination of HCV in vulnerable populations in four European cities. <i>International Journal of Infectious Diseases</i> , 2020, 101, 374-379.	1.5	8
61	Pay-it-forward gonorrhoea and chlamydia testing among men who have sex with men in China: a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 976-982.	4.6	30
62	Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: A modeling analysis. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108135.	1.6	20
63	Response to Commentary on Hancock et al . (2020): Low dead space syringes are just one component of an integrated package of care needed to tackle HCV and social exclusion among people who inject drugs. <i>Addiction</i> , 2020, 115, 2407-2408.	1.7	0
64	On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017. <i>BMJ Open</i> , 2020, 10, e036355.	0.8	4
65	Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 68.	1.0	26
66	Has resourcing of non-governmental harm reduction organizations in Ukraine improved HIV prevention and treatment outcomes for people who inject drugs? Findings from multiple behavioural surveys. <i>Journal of the International AIDS Society</i> , 2020, 23, e25608.	1.2	8
67	An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United Kingdom. <i>Value in Health</i> , 2020, 23, 1003-1011.	0.1	22
68	Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use) Tj ETQq0 0 0 rgB /Overl 10 Tf 5	0.8	0
69	Using data from "visible" populations to estimate the size and importance of "hidden" populations in an epidemic: A modelling technique. <i>Infectious Disease Modelling</i> , 2020, 5, 798-813.	1.2	0
70	The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study. <i>BMJ Global Health</i> , 2020, 5, e001875.	2.0	46
71	Cost and cost-effectiveness of a simplified treatment model with direct-acting antivirals for chronic hepatitis C in Cambodia. <i>Liver International</i> , 2020, 40, 2356-2366.	1.9	14
72	Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care. <i>BMJ</i> , The, 2020, 368, m322.	3.0	14

#	ARTICLE	IF	CITATIONS
73	Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 84, 173-181.	0.9	18
74	Prisons can also improve drug user health in the community. <i>Addiction</i> , 2020, 115, 914-915.	1.7	0
75	HIV infection risk and condom use among sex workers in Senegal: evidence from the list experiment method. <i>Health Policy and Planning</i> , 2020, 35, 408-415.	1.0	9
76	Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis. <i>The Lancet Global Health</i> , 2020, 8, e440-e450.	2.9	25
77	Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107899.	1.6	3
78	Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence. <i>International Journal of Drug Policy</i> , 2020, 77, 102656.	1.6	20
79	Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England. <i>Addiction</i> , 2020, 115, 1509-1521.	1.7	8
80	Presenting a conceptual framework for an HIV prevention and care continuum and assessing the feasibility of empirical measurement in Estonia: A case study. <i>PLoS ONE</i> , 2020, 15, e0240224.	1.1	2
81	Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. <i>Addiction</i> , 2019, 114, 150-166.	1.7	178
82	Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1388-1403.	1.0	11
83	Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa. <i>BMC Public Health</i> , 2019, 19, 996.	1.2	14
84	Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. <i>Addiction</i> , 2019, 114, 2267-2278.	1.7	28
85	The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2019, 73, 172-184.	1.6	67
86	Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation. <i>BMJ Open</i> , 2019, 9, e030183.	0.8	9
87	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol). <i>BMJ Open</i> , 2019, 9, e029538.	0.8	30
88	The cost of safe sex: estimating the price premium for unprotected sex during the Avahan HIV prevention programme in India. <i>Health Policy and Planning</i> , 2019, 34, 784-791.	1.0	10
89	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. <i>Lancet</i> , The, 2019, 394, 1560-1579.	6.3	404
90	Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). <i>BMC Infectious Diseases</i> , 2019, 19, 943.	1.3	28

#	ARTICLE	IF	CITATIONS
91	Pay-it-forward gonorrhoea and chlamydia testing among men who have sex with men in China: a study protocol for a three-arm cluster randomized controlled trial. <i>Infectious Diseases of Poverty</i> , 2019, 8, 76.	1.5	11
92	Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England. <i>Value in Health</i> , 2019, 22, 1248-1256.	0.1	12
93	Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data. <i>Journal of Viral Hepatitis</i> , 2019, 26, 541-551.	1.0	34
94	Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs. <i>Addiction</i> , 2019, 114, 560-570.	1.7	29
95	Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. <i>PLoS ONE</i> , 2019, 14, e0217964.	1.1	14
96	Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison. <i>American Journal of Epidemiology</i> , 2019, 188, 1539-1551.	1.6	29
97	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2019, 22, 693-703.	0.1	13
98	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 435-444.	3.7	145
99	Screening Strategies for Hepatitis C Virus. <i>Hepatology Communications</i> , 2019, 3, 321-324.	2.0	6
100	Integrated care of severe infectious diseases to people with substance use disorders; a systematic review. <i>BMC Infectious Diseases</i> , 2019, 19, 306.	1.3	14
101	A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?. <i>Journal of Infectious Diseases</i> , 2019, 220, 78-90.	1.9	29
102	Evaluating the impact of global fund withdrawal on needle and syringe provision, cost and use among people who inject drugs in Tijuana, Mexico: a costing analysis. <i>BMJ Open</i> , 2019, 9, e026298.	0.8	13
103	O08.2—Sexual behaviour, risk and sexually transmitted infections before and after the introduction of the PrEP impact trial. , 2019, , .		0
104	P018—Pay-it-forward gonorrhoea and chlamydia testing among chinese men who have sex with men: a cluster randomized controlled trial. , 2019, , .		1
105	HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco. <i>PLoS ONE</i> , 2019, 14, e0226166.	1.1	12
106	Integrating primary and secondary care to optimize hepatitis C treatment: development and evaluation of a multidisciplinary educational Masterclass series. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, v24-v30.	1.3	7
107	The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, v5-v16.	1.3	18
108	Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, v31-v38.	1.3	9

#	ARTICLE	IF	CITATIONS
109	Hepatitis case finding among migrants in primary care. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 3-4.	3.7	4
110	High response and reinfection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. <i>Journal of Viral Hepatitis</i> , 2019, 26, 519-528.	1.0	48
111	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 135-184.	3.7	370
112	The impact of opiate substitution treatment on mortality risk in drug addicts: a natural experiment study. <i>Health Services and Delivery Research</i> , 2019, 7, 1-92.	1.4	3
113	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. <i>Journal of Hepatology</i> , 2018, 68, 402-411.	1.8	105
114	The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. <i>Addiction</i> , 2018, 113, 1461-1476.	1.7	83
115	How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity. <i>European Journal of Health Economics</i> , 2018, 19, 1053-1066.	1.4	196
116	Differences in risk behaviours and HIV status between primary amphetamines and opioid injectors in Estonia and Russia. <i>International Journal of Drug Policy</i> , 2018, 53, 96-105.	1.6	8
117	Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. <i>International Journal of Epidemiology</i> , 2018, 47, 550-560.	0.9	64
118	Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 303-314.	1.4	20
119	The cost-effectiveness of multi-purpose <sc>HIV</sc> and pregnancy prevention technologies in South Africa. <i>Journal of the International AIDS Society</i> , 2018, 21, e25064.	1.2	23
120	Scaling up HCV prevention and treatment interventions in rural United States model projections for tackling an increasing epidemic. <i>Addiction</i> , 2018, 113, 173-182.	1.7	71
121	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. <i>Addiction</i> , 2018, 113, 545-563.	1.7	242
122	Early antiretroviral therapy and daily pre-exposure prophylaxis for <sc>HIV</sc> prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study. <i>Journal of the International AIDS Society</i> , 2018, 21, e25208.	1.2	43
123	The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. <i>Lancet Public Health</i> , The, 2018, 3, e429-e437.	4.7	33
124	A mechanistic hydro-epidemiological model of liver fluke risk. <i>Journal of the Royal Society Interface</i> , 2018, 15, 20180072.	1.5	18
125	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1397-1409.	4.6	147
126	Estimating the contribution of key populations towards the spread of <sc>HIV</sc> in Dakar, Senegal. <i>Journal of the International AIDS Society</i> , 2018, 21, e25126.	1.2	30

#	ARTICLE	IF	CITATIONS
127	Usage of low dead space syringes and association with hepatitis C prevalence amongst people who inject drugs in the UK. <i>Drug and Alcohol Dependence</i> , 2018, 192, 118-124.	1.6	8
128	Crowdsourcing to expand HIV testing among men who have sex with men in China: A closed cohort stepped wedge cluster randomized controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002645.	3.9	110
129	Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. <i>Addiction</i> , 2018, 113, 2118-2131.	1.7	15
130	Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings—what is required to achieve the WHO's HCV elimination targets?. <i>Addiction</i> , 2018, 113, 1727-1738.	1.7	30
131	The effect of HIV prevention products on incentives to supply condomless commercial sex among female sex workers in South Africa. <i>Health Economics (United Kingdom)</i> , 2018, 27, 1550-1566.	0.8	16
132	Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. <i>Lancet HIV</i> , 2018, 5, e578-e587.	2.1	29
133	Cost of provision of opioid substitution therapy provision in Tijuana, Mexico. <i>Harm Reduction Journal</i> , 2018, 15, 28.	1.3	20
134	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission. <i>Lancet</i> , 2018, 392, 312-358.	6.3	230
135	Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence. <i>Aids</i> , 2018, 32, 1343-1352.	1.0	33
136	Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa. <i>Medical Decision Making</i> , 2018, 38, 120-133.	1.2	79
137	Integrated Hepatitis C Care for People Who Inject Drugs (Heplink): Protocol for a Feasibility Study in Primary Care. <i>JMIR Research Protocols</i> , 2018, 7, e149.	0.5	9
138	A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs. <i>Eurosurveillance</i> , 2018, 23, .	3.9	8
139	First estimates of the global and regional incidence of neonatal herpes infection. <i>The Lancet Global Health</i> , 2017, 5, e300-e309.	2.9	164
140	Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. <i>Addiction</i> , 2017, 112, 1302-1314.	1.7	80
141	Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?. <i>Addiction</i> , 2017, 112, 1290-1299.	1.7	42
142	Integrated opioid substitution therapy and HIV care: a qualitative systematic review and synthesis of client and provider experiences. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1119-1128.	0.6	27
143	New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs—announcing an <i>Addiction</i> series. <i>Addiction</i> , 2017, 112, 1126-1127.	1.7	2
144	Impact of opioid substitution therapy on the HIV prevention benefit of antiretroviral therapy for people who inject drugs. <i>Aids</i> , 2017, 31, 1181-1190.	1.0	22

#	ARTICLE	IF	CITATIONS
145	Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact. <i>International Journal of Epidemiology</i> , 2017, 46, 1582-1592.	0.9	25
146	Rejoinder to: Implementation of low dead space syringes in response to an outbreak of HIV among people who inject drugs: A response to Kesten et al.. <i>International Journal of Drug Policy</i> , 2017, 43, 142-143.	1.6	0
147	How to eliminate HCV infection by antiviral treatment. <i>Journal of Hepatology</i> , 2017, 67, 5-6.	1.8	16
148	The promise of multipurpose pregnancy, STI, and HIV prevention. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 21-22.	4.6	13
149	Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. <i>The Lancet Global Health</i> , 2017, 5, e1192-e1207.	2.9	1,020
150	Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1303-1316.	4.6	199
151	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. <i>The Cochrane Library</i> , 2017, 2017, CD012021.	1.5	158
152	Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. <i>The Lancet Global Health</i> , 2017, 5, e1208-e1220.	2.9	334
153	Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. <i>Harm Reduction Journal</i> , 2017, 14, 19.	1.3	33
154	Acceptability of low dead space syringes and implications for their introduction: A qualitative study in the West of England. <i>International Journal of Drug Policy</i> , 2017, 39, 99-108.	1.6	19
155	Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling. <i>Public Health Research</i> , 2017, 5, 1-118.	0.5	20
156	Importance and Contribution of Community, Social, and Healthcare Risk Factors for Hepatitis C Infection in Pakistan. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1920-1928.	0.6	22
157	Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs. <i>AIDS Reviews</i> , 2017, 19, 97-104.	0.5	4
158	Hepatitis C "Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2016, 17, 366.	0.7	13
159	HIV treatment as prevention among people who inject drugs " a re-evaluation of the evidence. <i>International Journal of Epidemiology</i> , 2016, 46, dyw180.	0.9	19
160	Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. <i>Hepatology</i> , 2016, 63, 1796-1808.	3.6	58
161	Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? <i>Epidemiological and Modeling Insights. Clinical Infectious Diseases</i> , 2016, 62, 1072-1080.	2.9	122
162	Parameterising User Uptake in Economic Evaluations: The role of discrete choice experiments. <i>Health Economics (United Kingdom)</i> , 2016, 25, 116-123.	0.8	30

#	ARTICLE	IF	CITATIONS
163	Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV prevention. <i>Addiction</i> , 2016, 111, 1512-1515.	1.7	7
164	New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. <i>Journal of Viral Hepatitis</i> , 2016, 23, 631-643.	1.0	37
165	The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. <i>Lancet, The</i> , 2016, 388, 1228-1248.	6.3	213
166	Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2016, 63, 1094-1104.	2.9	174
167	Potential impact of pre-exposure prophylaxis for female sex workers and men who have sex with men in Bangalore, India: a mathematical modelling study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20942.	1.2	18
168	Preferences for ARV-based HIV prevention methods among men and women, adolescent girls and female sex workers in Gauteng Province, South Africa: a protocol for a discrete choice experiment. <i>BMJ Open</i> , 2016, 6, e010682.	0.8	20
169	Data and methods to characterize the role of sex work and to inform sex work programs in generalized HIV epidemics: evidence to challenge assumptions. <i>Annals of Epidemiology</i> , 2016, 26, 557-569.	0.9	37
170	Comparing the impact of increasing condom use or HIV pre-exposure prophylaxis (PrEP) use among female sex workers. <i>Epidemics</i> , 2016, 14, 62-70.	1.5	17
171	Reply. <i>Hepatology</i> , 2016, 64, 1822-1823.	3.6	0
172	Public health and international drug policy. <i>Lancet, The</i> , 2016, 387, 1427-1480.	6.3	460
173	What Determines HIV Prevention Costs at Scale? Evidence from the Avahan Programme in India. <i>Health Economics (United Kingdom)</i> , 2016, 25, 67-82.	0.8	16
174	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. <i>Journal of Hepatology</i> , 2016, 65, 17-25.	1.8	157
175	Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 797-808.	4.6	542
176	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, 2016, .		38
177	The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?. <i>PLoS ONE</i> , 2016, 11, e0156213.	1.1	41
178	Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. <i>Aids</i> , 2015, 29, 2035-2044.	1.0	39
179	HCV treatment as prevention in prison: Key issues. <i>Hepatology</i> , 2015, 61, 402-403.	3.6	12
180	<sc>HCV</sc> treatment rates and sustained viral response among people who inject drugs in seven <sc>UK</sc> sites: real world results and modelling of treatment impact. <i>Journal of Viral Hepatitis</i> , 2015, 22, 399-408.	1.0	86

#	ARTICLE	IF	CITATIONS
181	The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and) Tj ETQq1 1 0.784314 rgBT /Over	1.5	119
182	Is the promise of methadone Kenya's solution to managing HIV and addiction? A mixed-method mathematical modelling and qualitative study. <i>BMJ Open</i> , 2015, 5, e007198-e007198.	0.8	43
183	Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa. <i>Aids</i> , 2015, 29, 1701-1710.	1.0	25
184	Hepatitis C virus treatment as prevention in people who inject drugs. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 576-582.	1.3	78
185	Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. <i>PLoS ONE</i> , 2015, 10, e0140765.	1.1	464
186	Determinants of HIV testing among Nigerian couples: a multilevel modelling approach. <i>Health Policy and Planning</i> , 2015, 30, 579-592.	1.0	23
187	The cost-effectiveness of 10 antenatal syphilis screening and treatment approaches in Peru, Tanzania, and Zambia. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 130, S73-80.	1.0	23
188	Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data. <i>Journal of the Royal Society Interface</i> , 2015, 12, 20141197.	1.5	14
189	Potential Impact of Existing Interventions and of Antiretroviral Use in Female Sex Workers on Transmission of HIV in Burkina Faso. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, S180-S188.	0.9	19
190	What Really Is a Concentrated HIV Epidemic and What Does It Mean for West and Central Africa? Insights From Mathematical Modeling. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, S74-S82.	0.9	35
191	Editorial Commentary: The Impact of Opiate Substitution Therapy and Highly Active Antiretroviral Therapy on Mortality Risk Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2015, 61, 1166-1168.	2.9	4
192	Influence of different drugs on HIV risk in people who inject: systematic review and meta-analysis. <i>Addiction</i> , 2015, 110, 572-584.	1.7	48
193	The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. <i>BMC Medicine</i> , 2015, 13, 198.	2.3	54
194	The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001869.	3.9	15
195	Global Estimates of Prevalent and Incident Herpes Simplex Virus Type 2 Infections in 2012. <i>PLoS ONE</i> , 2015, 10, e114989.	1.1	366
196	The Cost of Providing Combined Prevention and Treatment Services, Including ART, to Female Sex Workers in Burkina Faso. <i>PLoS ONE</i> , 2014, 9, e100107.	1.1	14
197	Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. <i>PLoS ONE</i> , 2014, 9, e103345.	1.1	184
198	Community Mobilisation and Empowerment Interventions as Part of HIV Prevention for Female Sex Workers in Southern India: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2014, 9, e110562.	1.1	23

#	ARTICLE	IF	CITATIONS
199	Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis. <i>BMC Infectious Diseases</i> , 2014, 14, S18.	1.3	5
200	<i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> infection in HIV-1-infected women taking antiretroviral therapy: a prospective cohort study from Burkina Faso: Table A1. <i>Sexually Transmitted Infections</i> , 2014, 90, 100-103.	0.8	12
201	Exploring the population-level impact of antiretroviral treatment. <i>Aids</i> , 2014, 28, S61-S72.	1.0	14
202	The HIV care cascade and antiretroviral therapy in female sex workers: implications for HIV prevention. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1203-1219.	2.0	35
203	Calcutta HIV Model Projections and the Impact of PrEP. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A70-A71.	0.5	0
204	Controlling HIV among people who inject drugs in Eastern Europe and Central Asia: Insights from modelling. <i>International Journal of Drug Policy</i> , 2014, 25, 1163-1173.	1.6	37
205	Relationship between exposure to the Avahan intervention and levels of reported condom use among men who have sex with men in southern India. <i>BMC Public Health</i> , 2014, 14, 1245.	1.2	4
206	Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in <i>JVH</i> Special Issue. <i>Journal of Viral Hepatitis</i> , 2014, 21, e167-8.	1.0	2
207	Commentary on Nolan et al. (2014): Opiate substitution treatment and hepatitis C virus prevention: building an evidence base?. <i>Addiction</i> , 2014, 109, 2060-2061.	1.7	13
208	Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. <i>BMC Infectious Diseases</i> , 2014, 14, 14.	1.3	28
209	Mathematical Modelling to Estimate the Impact and Cost-effectiveness of TasP, PrEP and Condom Promotion for Serodiscordant Couples in Nigeria. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A73-A73.	0.5	0
210	Mathematical Modelling of the Impact of PrEP for Female Sex Workers and Men Who Have Sex with Men upon HIV Incidence and Survival in Southern India. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A161-A162.	0.5	1
211	Cost-effectiveness of HIV prevention for high-risk groups at scale: an economic evaluation of the Avahan programme in south India. <i>The Lancet Global Health</i> , 2014, 2, e531-e540.	2.9	38
212	Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. <i>Journal of Viral Hepatitis</i> , 2014, 21, 616-623.	1.0	14
213	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. <i>The Lancet Global Health</i> , 2014, 2, e23-e34.	2.9	188
214	Modeling the impact of early antiretroviral therapy for adults coinfecting with HIV and hepatitis B or C in South Africa. <i>Aids</i> , 2014, 28, S35-S46.	1.0	23
215	Community Mobilization and Empowerment of Female Sex Workers in Karnataka State, South India: Associations With HIV and Sexually Transmitted Infection Risk. <i>American Journal of Public Health</i> , 2014, 104, 1516-1525.	1.5	63
216	Cervicovaginal HIV-1 Shedding in Women Taking Antiretroviral Therapy in Burkina Faso. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 237-245.	0.9	27

#	ARTICLE	IF	CITATIONS
217	Antiretroviral Therapy Uptake, Attrition, Adherence and Outcomes among HIV-Infected Female Sex Workers: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e105645.	1.1	113
218	The Costs of Scaling Up HIV Prevention for High Risk Groups: Lessons Learned from the Avahan Programme in India. PLoS ONE, 2014, 9, e106582.	1.1	14
219	Optimal Allocation of Resources in Female Sex Worker Targeted HIV Prevention Interventions: Model Insights from Avahan in South India. PLoS ONE, 2014, 9, e107066.	1.1	9
220	A mathematical model for HIV and hepatitis C co-infection and its assessment from a statistical perspective. Epidemics, 2013, 5, 56-66.	1.5	19
221	How cost-effective is hepatitis C virus treatment for people who inject drugs?. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 590-592.	1.4	10
222	Assessment of the population-level effectiveness of the Avahan HIV-prevention programme in South India: a preplanned, causal-pathway-based modelling analysis. The Lancet Global Health, 2013, 1, e289-e299.	2.9	64
223	Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?. Drug and Alcohol Dependence, 2013, 132, 172-181.	1.6	40
224	HIV transmission from drug injectors to partners who do not inject, and beyond: Modelling the potential for a generalized heterosexual epidemic in St. Petersburg, Russia. Drug and Alcohol Dependence, 2013, 133, 242-247.	1.6	19
225	Could low dead-space syringes really reduce HIV transmission to low levels?. International Journal of Drug Policy, 2013, 24, 8-14.	1.6	24
226	Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open, 2013, 3, e003153.	0.8	74
227	Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy. Clinical Infectious Diseases, 2013, 57, S39-S45.	2.9	275
228	Prioritizing Congenital Syphilis Control in South China: A Decision Analytic Model to Inform Policy Implementation. PLoS Medicine, 2013, 10, e1001375.	3.9	11
229	Financing Essential HIV Services: A New Economic Agenda. PLoS Medicine, 2013, 10, e1001567.	3.9	36
230	Commentary on de Vos <i>et al</i> . (2013): Can ecological trends in HIV or HCV incidence be used to assess intervention impact?. Addiction, 2013, 108, 1082-1083.	1.7	2
231	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology, 2013, 58, 1598-1609.	3.6	431
232	Can the UNAIDS modes of transmission model be improved?. Aids, 2013, 27, 2623-2635.	1.0	22
233	Positive impact of a large-scale HIV prevention programme among female sex workers and clients in South India. Aids, 2013, 27, 1449-1460.	1.0	44
234	Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. Aids, 2013, 27, 2551-2557.	1.0	152

#	ARTICLE	IF	CITATIONS
235	The Impact of Syphilis Screening among Female Sex Workers in China: A Modelling Study. PLoS ONE, 2013, 8, e55622.	1.1	16
236	How Much Demand for New HIV Prevention Technologies Can We Really Expect? Results from a Discrete Choice Experiment in South Africa. PLoS ONE, 2013, 8, e83193.	1.1	53
237	Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ, The, 2012, 345, e5945-e5945.	3.0	363
238	HIV Treatment as Prevention: Optimising the Impact of Expanded HIV Treatment Programmes. PLoS Medicine, 2012, 9, e1001258.	3.9	50
239	The More You Look, the More You Find: Effects of Hepatitis C Virus Testing Interval on Reinfection Incidence and Clearance and Implications for Future Vaccine Study Design. Journal of Infectious Diseases, 2012, 205, 1342-1350.	1.9	64
240	Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings—Implications for intervention impact. Drug and Alcohol Dependence, 2012, 123, 122-131.	1.6	34
241	Respondent driven sampling and community structure in a population of injecting drug users, Bristol, UK. Drug and Alcohol Dependence, 2012, 126, 324-332.	1.6	19
242	Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Medical Journal of Australia, 2012, 196, 638-641.	0.8	51
243	Commentary on Mehta <i>et al</i> . (2012): Natural history of injecting drug use. Addiction, 2012, 107, 359-360.	1.7	1
244	Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction, 2012, 107, 1984-1995.	1.7	128
245	Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology, 2012, 55, 49-57.	3.6	194
246	Apples and oranges? Interpreting success in HIV prevention trials. Contraception, 2011, 83, 10-15.	0.8	14
247	Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug and Alcohol Dependence, 2011, 113, 83-85.	1.6	33
248	Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. Journal of Hepatology, 2011, 54, 1137-1144.	1.8	199
249	Optimal Control of Hepatitis C Antiviral Treatment Programme Delivery for Prevention amongst a Population of Injecting Drug Users. PLoS ONE, 2011, 6, e22309.	1.1	36
250	The Cost-Effectiveness of Herpes Simplex Virus-2 Suppressive Therapy With Daily Aciclovir for Delaying HIV Disease Progression Among HIV-1-Infected Women in South Africa. Sexually Transmitted Diseases, 2011, 38, 401-409.	0.8	16
251	The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction, 2011, 106, 1978-1988.	1.7	271
252	Mathematical modelling of hepatitis C treatment for injecting drug users. Journal of Theoretical Biology, 2011, 274, 58-66.	0.8	86

#	ARTICLE	IF	CITATIONS
253	The costs of HIV prevention for different target populations in Mumbai, Thane and Bangalore. <i>BMC Public Health</i> , 2011, 11, S7.	1.2	10
254	A dose-response relationship between exposure to a large-scale HIV preventive intervention and consistent condom use with different sexual partners of female sex workers in southern India. <i>BMC Public Health</i> , 2011, 11, S8.	1.2	41
255	Modelling the interactions between herpes simplex virus type 2 and HIV: implications for the HIV epidemic in southern India. <i>Sexually Transmitted Infections</i> , 2011, 87, 22-27.	0.8	9
256	Joint Modeling of HCV and HIV Infections among Injecting Drug Users in Italy Using Repeated Cross-Sectional Prevalence Data. <i>Statistical Communications in Infectious Diseases</i> , 2011, 3, .	0.2	3
257	Attaining realistic and substantial reductions in HIV incidence: model projections of combining microbicide and male circumcision interventions in rural Uganda. <i>Sexually Transmitted Infections</i> , 2011, 87, 635-639.	0.8	8
258	Promoting recovery and preventing drug-related mortality: competing risks?. <i>Journal of Public Health</i> , 2011, 33, 332-334.	1.0	13
259	The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh. <i>Addiction</i> , 2010, 105, 319-328.	1.7	29
260	Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. <i>Addiction</i> , 2010, 105, 311-318.	1.7	77
261	Using mathematical modelling to estimate the impact of periodic presumptive treatment on the transmission of sexually transmitted infections and HIV among female sex workers. <i>Sexually Transmitted Infections</i> , 2010, 86, 163-168.	0.8	31
262	Remodelling core group theory: the role of sustaining populations in HIV transmission. <i>Sexually Transmitted Infections</i> , 2010, 86, iii85-iii92.	0.8	26
263	Interim modelling analysis to validate reported increases in condom use and assess HIV infections averted among female sex workers and clients in southern India following a targeted HIV prevention programme. <i>Sexually Transmitted Infections</i> , 2010, 86, i33-i43.	0.8	35
264	To what extent is the HIV epidemic in southern India driven by commercial sex? A modelling analysis. <i>Aids</i> , 2010, 24, 2563-2572.	1.0	52
265	Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. <i>BMJ: British Medical Journal</i> , 2010, 341, c5475-c5475.	2.4	250
266	Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. <i>Lancet, The</i> , 2010, 376, 285-301.	6.3	382
267	Policy resistance to harm reduction for drug users and potential effect of change. <i>BMJ: British Medical Journal</i> , 2010, 341, c3439-c3439.	2.4	37
268	Dynamic Modeling of Herpes Simplex Virus Type-2 (HSV-2) Transmission: Issues in Structural Uncertainty. <i>Bulletin of Mathematical Biology</i> , 2009, 71, 720-749.	0.9	26
269	If cannabis caused schizophrenia—how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. <i>Addiction</i> , 2009, 104, 1856-1861.	1.7	51
270	Frequency, factors and costs associated with injection site infections: Findings from a national multi-site survey of injecting drug users in England. <i>BMC Infectious Diseases</i> , 2008, 8, 120.	1.3	97

#	ARTICLE	IF	CITATIONS
271	Using mathematical modelling to investigate the plausibility of attributing observed antenatal clinic declines to a female sex worker intervention in Karnataka state, India. <i>Aids</i> , 2008, 22, S149-S164.	1.0	24
272	The impact of out-migrants and out-migration on the HIV/AIDS epidemic: a case study from south-west India. <i>Aids</i> , 2008, 22, S165-S181.	1.0	32
273	Using Modeling to Explore the Degree to Which a Microbicide's Sexually Transmitted Infection Efficacy May Contribute to the HIV Effectiveness Measured in Phase 3 Microbicide Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 460-467.	0.9	17
274	Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. <i>International Journal of Epidemiology</i> , 2007, 36, 396-405.	0.9	79
275	Could the CARE-SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh?. <i>Addiction</i> , 2007, 102, 114-125.	1.7	27
276	Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. <i>Addiction</i> , 2007, 102, 597-606.	1.7	79
277	Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. <i>BMC Public Health</i> , 2007, 7, 195.	1.2	48
278	RESPONSE TO THE COMMENTARIES. <i>Addiction</i> , 2007, 102, 516-518.	1.7	2
279	Model Projections on the Required Coverage of Syringe Distribution to Prevent HIV Epidemics Among Injecting Drug Users. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 355-361.	0.9	64
280	The Importance of Context: Model Projections on How Microbicide Impact Could Be Affected by the Underlying Epidemiologic and Behavioral Situation in 2 African Settings. <i>Sexually Transmitted Diseases</i> , 2006, 33, 397-405.	0.8	33
281	Reducing the burden of sexually transmitted infections in resource-limited settings: the role of improved diagnostics. <i>Nature</i> , 2006, 444, 59-72.	13.7	46
282	The Cost-Effectiveness of Expanding Harm Reduction Activities for Injecting Drug Users in Odessa, Ukraine. <i>Sexually Transmitted Diseases</i> , 2006, 33, S89-S102.	0.8	52
283	Are Targeted HIV Prevention Activities Cost-Effective in High Prevalence Settings? Results From a Sexually Transmitted Infection Treatment Project for Sex Workers in Johannesburg, South Africa. <i>Sexually Transmitted Diseases</i> , 2006, 33, S122-S132.	0.8	47
284	Care should be taken when promoting microbicide use among sex workers who are able to use condoms consistently: response to Smith et al. (2005). <i>Aids</i> , 2006, 20, 303-305.	1.0	1
285	Detection of Gonococcal Infection. <i>Molecular Diagnosis and Therapy</i> , 2005, 9, 175-179.	1.3	8
286	Measuring the quality of hospital tuberculosis services: a prospective study in four Zimbabwe hospitals. <i>International Journal for Quality in Health Care</i> , 2005, 17, 287-292.	0.9	8
287	Detection of Gonococcal Infection. <i>Molecular Diagnosis and Therapy</i> , 2005, 9, 175-179.	1.3	21
288	Detection of gonococcal infection : pros and cons of a rapid test. <i>Molecular Diagnosis and Therapy</i> , 2005, 9, 175-9.	1.3	12

#	ARTICLE	IF	CITATIONS
289	Condoms and prevention of HIV. <i>BMJ: British Medical Journal</i> , 2004, 329, 185-186.	2.4	39
290	The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. <i>Addiction</i> , 2004, 99, 1565-1576.	1.7	32
291	Injecting drug use and the sexual transmission of HIV: simple model insights. <i>International Journal of Drug Policy</i> , 2003, 14, 89-93.	1.6	10
292	Shifts in condom use following microbicide introduction. <i>Aids</i> , 2003, 17, 1227-1237.	1.0	120
293	The impact of an HIV prevention intervention for injecting drug users in Svetlogorsk, Belarus: model predictions. <i>International Journal of Drug Policy</i> , 2002, 13, 149-164.	1.6	24
294	The impact of microbicides on HIV and STD transmission: model projections. <i>Aids</i> , 2001, 15, S43-S44.	1.0	20
295	Integrating Hepatitis C Care for opioid substitution treatment patients attending general practice: Feasibility, Clinical and Cost Effectiveness (Preprint). <i>Interactive Journal of Medical Research</i> , 0, , .	0.6	2